Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3096 | 0.3096 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1191 | 0.1191 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.2218 | 0.3289 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.2218 | 0.3289 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3096 | 0.3096 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3096 | 0.3096 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.6742 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.2218 | 0.3289 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.3096 | 0.3096 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3096 | 0.3096 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.3096 | 0.3096 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3096 | 0.3096 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.6742 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.6742 | 1 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3096 | 0.4591 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3096 | 0.4591 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1191 | 0.1767 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1191 | 0.1767 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3096 | 0.4591 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3096 | 0.4591 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2218 | 0.3289 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3096 | 0.4591 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3096 | 0.4591 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 96 uM | PubChem BioAssay. Dose response counterscreen for EBI2 assay utilizing the enzyme, b-galactosidase. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 4.4668 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.